Menu:
Alzheimer's | Cardiopulmonary | Chronic Pain | Dermatitis | Diabetes | Epilepsy | Fibromyalgia | Gastric Disorders | Geriatrics | Glaucoma | Headaches | Hypertension | Macular Degeneration | Managed Care | Multiple Sclerosis | Neonatology | Nephrology | Neuroscience | Oncology | Pediatrics | Psychiatric | Rheumatism | Sleep Disorders | Spasticity | Stroke | Womens Health
Purchase our video content securely online with PayPal:
Dermatitis Educational Programming
Advances in Treatment of Herpes Zoster Infection
Program no. MA-0616M, 120 minutes
Presenters: Karl Buetner, MD; Richard Whitley, MD; Robert Dworkin, MD; John F. Flahery, PharmD; John Wolf, MD
The Pain Benefit for Anti-Herpetic Therapy in the Elderly; Therapeutic Advances in H. Zoster; Pharmacokinetics and Differentiation of Anti-Viral Therapy; Herpes Zoster: Pain Analysis.
Management of Herpes Zoster
Program no. MA-1012M, 120 minutes
Presenters: Myron J. Levin, MD; Larry Gelb, MD; Michael Oxman, MD; Allyn Bandell, PharmD; Peter Watson, MD; Wayne Gray, PhD
A panel of leading dermatologists, infectious disease physicians and managed care professionals will apply disease management principles to the diagnosis and treatment of Herpes Zoster.
Advances in Treatment of Herpes Zoster
Program no. MB-0302M, 120 minutes
Presenters: Karl Buetner, MD; Richard Whitley, MD; Robert Dworkin, MD; John F. Flahery, PharmD; John Wolf, MD
The Pain Benefit for Anti-Herpetic Therapy in the Elderly; Therapeutic Advances in H. Zoster; Pharmacokinetics and Differentiation of Anti-Viral Therapy; Herpes Zoster: Pain Analysis.
Advances in the Treatment of Genital Herpes
Program no. MC-0516M, 90 minutes
Presenters: Antonio Buzaid, MD; Merick Ross, MD
Adjuvant Therapy: Interferon and New Advances in Patients with Advanced Diseases; Diagnosis and Prognosis of Primary Melanoma.
Recent Advances in Treatment of Cutaneous Fungal Infections (Onychomycosis)
Program no. MD-0408M, 90 minutes
Presenters: Norman Guzick, MD; Phoebe Rich, MD - John Wolf, MD; H. Irving Katz, MD
Psychosocial Ramifications and Epidemiology; Diagnosis and Differential; Current Treatment Strategies for Onychomycosis; Safety Concerns Regarding Drug Interaction Potential and Liver Metabolism.
Pressure Ulcers: Prevention & Treatment
Program no. ME-0526N, 60 minutes
Presenters: Mary Y. Sieggreen, RN, CS, CNP, CVN, MSN; Maria Palleschi, MSN, RN, CCRN; JoAnn Maklebust, MSN, RN, CS, NP.
Describes the most common pressure ulcer risk factors and the wound healing process; Identify methods for pressure ulcer prevention and treatment.
Antifungal Therapy Beyond the Year 2000
Program no. ME-0618M, 150 minutes
Presenters: Boni E. Elewski, MD; Hideoki Ogawa; David T. Roberts; Bardur Sigurgeirsson; Christa de Cuyper; D. O'Sullivan; Irving Katz, MD; E.G.V. Evans, PhD, FRCPath; R.J. Hay, DM, FRCPath
Understand the newest treatment regimens in onychomycosis therapy. Discuss the safety profile of antimycotics including side effects and drug interactions. Recognize the challenges in the management of onychomycosis. Discuss the long-term outcome of onychomycosis treatment.
MEDIVISION ™ does not warrant the accuracy of this information, and it is intended as a supplement to, and NOT a substitute for, the knowledge, skill, and judgment of healthcare professionals. If you have questions about health care, please consult a physician or other health care professionals.